Skip to main content
Erschienen in: Drugs & Therapy Perspectives 8/2023

21.07.2023 | Disease Management

Manage early morning ADHD symptoms and functional impairment with treatments that are effective from awakening

verfasst von: Tina Nie

Erschienen in: Drugs & Therapy Perspectives | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

The early morning routine before school can be a particularly challenging time for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Morning-dosed stimulants often fail to adequately address early morning ADHD symptoms and impaired functioning, due to the delay in their onset of effect, which has a significant impact on the entire family. Clinicians should consider treatments that are effective from awakening, such as methylphenidate delayed release/extended release administered in the evening, methylphenidate transdermal system applied to the skin before awakening, or long-acting non-stimulants such as atomoxetine and guanfacine extended release, to improve ADHD symptoms and functioning during the early morning.
Literatur
1.
Zurück zum Zitat Childress AC, Yu KR, Cuthbertson L. Early morning ADHD symptoms and functional impairment: impact on patients and caregivers, and pharmacological approaches to management. CNS Drugs. 2023;37(1):31–44.CrossRefPubMed Childress AC, Yu KR, Cuthbertson L. Early morning ADHD symptoms and functional impairment: impact on patients and caregivers, and pharmacological approaches to management. CNS Drugs. 2023;37(1):31–44.CrossRefPubMed
2.
Zurück zum Zitat Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.CrossRefPubMed Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.CrossRefPubMed
3.
Zurück zum Zitat CADDRA-Canadian ADHD Resource Alliance. Canadian ADHD practice guidelines, 4.1 edition. Toronto: CADDRA;2020. CADDRA-Canadian ADHD Resource Alliance. Canadian ADHD practice guidelines, 4.1 edition. Toronto: CADDRA;2020.
4.
Zurück zum Zitat Sallee FR. Early morning functioning in stimulant-treated children and adolescents with attention-deficit/hyperactivity disorder, and its impact on caregivers. J Child Adolesc Psychopharmacol. 2015;25(7):558–65.CrossRefPubMedPubMedCentral Sallee FR. Early morning functioning in stimulant-treated children and adolescents with attention-deficit/hyperactivity disorder, and its impact on caregivers. J Child Adolesc Psychopharmacol. 2015;25(7):558–65.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Faraone SV, Schachar RJ, Barkley RA, et al. Early morning functional impairments in stimulant-treated children with attention-deficit/hyperactivity disorder versus controls: impact on the family. J Child Adolesc Psychopharmacol. 2017;27(8):715–22.CrossRefPubMedPubMedCentral Faraone SV, Schachar RJ, Barkley RA, et al. Early morning functional impairments in stimulant-treated children with attention-deficit/hyperactivity disorder versus controls: impact on the family. J Child Adolesc Psychopharmacol. 2017;27(8):715–22.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383(11):1050–6.CrossRefPubMed Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383(11):1050–6.CrossRefPubMed
7.
Zurück zum Zitat Bolea-Alamanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179–203.CrossRefPubMed Bolea-Alamanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179–203.CrossRefPubMed
8.
Zurück zum Zitat Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(6):474–82.CrossRefPubMedPubMedCentral Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(6):474–82.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Coghill D, Soutullo C, d’Aubuisson C, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health. 2008;2(1):31.CrossRefPubMedPubMedCentral Coghill D, Soutullo C, d’Aubuisson C, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health. 2008;2(1):31.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Döpfner M, Görtz-Dorten A, Breuer D, et al. An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. Eur Child Adolesc Psychiatry. 2011;20(Suppl 2):243–55.CrossRefPubMedCentral Döpfner M, Görtz-Dorten A, Breuer D, et al. An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. Eur Child Adolesc Psychiatry. 2011;20(Suppl 2):243–55.CrossRefPubMedCentral
11.
Zurück zum Zitat Kollins SH, Braeckman R, Guenther S, et al. A randomized, controlled laboratory classroom study of serdexmethylphenidate and d-methylphenidate capsules in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021;31(9):597–609.CrossRefPubMed Kollins SH, Braeckman R, Guenther S, et al. A randomized, controlled laboratory classroom study of serdexmethylphenidate and d-methylphenidate capsules in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021;31(9):597–609.CrossRefPubMed
12.
Zurück zum Zitat Wilens TE, Hammerness P, Martelon M, et al. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(5):548–56.CrossRefPubMed Wilens TE, Hammerness P, Martelon M, et al. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(5):548–56.CrossRefPubMed
13.
Zurück zum Zitat Childress AC, Cutler AJ, Marraffino A, et al. A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder: an evaluation of safety and efficacy throughout the day and across settings. J Child Adolesc Psychopharmacol. 2020;30(1):2–14.CrossRefPubMedPubMedCentral Childress AC, Cutler AJ, Marraffino A, et al. A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder: an evaluation of safety and efficacy throughout the day and across settings. J Child Adolesc Psychopharmacol. 2020;30(1):2–14.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-8.CrossRefPubMed Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-8.CrossRefPubMed
16.
Zurück zum Zitat Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896–901.CrossRefPubMed Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896–901.CrossRefPubMed
17.
Zurück zum Zitat Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29(12):1573–85.CrossRefPubMed Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29(12):1573–85.CrossRefPubMed
18.
Zurück zum Zitat Wehmeier PM, Dittmann RW, Schacht A, et al. Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies. Child Adolesc Psychiatry Ment Health. 2009;3(1):5.CrossRefPubMedPubMedCentral Wehmeier PM, Dittmann RW, Schacht A, et al. Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies. Child Adolesc Psychiatry Ment Health. 2009;3(1):5.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Wilens TE, McBurnett K, Turnbow J, et al. Morning and evening effects of guanfacine extended release adjunctive to psychostimulants in pediatric ADHD. J Atten Disord. 2017;21(2):110–9.CrossRefPubMed Wilens TE, McBurnett K, Turnbow J, et al. Morning and evening effects of guanfacine extended release adjunctive to psychostimulants in pediatric ADHD. J Atten Disord. 2017;21(2):110–9.CrossRefPubMed
Metadaten
Titel
Manage early morning ADHD symptoms and functional impairment with treatments that are effective from awakening
verfasst von
Tina Nie
Publikationsdatum
21.07.2023
Verlag
Springer International Publishing
Erschienen in
Drugs & Therapy Perspectives / Ausgabe 8/2023
Print ISSN: 1172-0360
Elektronische ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-023-01013-0

Weitere Artikel der Ausgabe 8/2023

Drugs & Therapy Perspectives 8/2023 Zur Ausgabe